A Phase 2 interventional study of Akynzeo in Chemotherapy Induced Nausea and Vomiting, sponsored by Simon Williamson Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Simon Williamson Clinic · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 286 studies in Vomiting with a site in United States — 25 open to participants now, 27 under way, 5 of them phase 3. Vomiting · United States.
Among the 286 studies in Vomiting with a site in United States, this one is the 113th largest by enrollment of the 256 interventional ones that give a count, is one of 7 that started in 2023, is one of 57 in phase 2, and was the 266th registered.
794 studies on the registry are indexed under Vomiting; 98 are open to participants now.
Browse Vomiting studies →25 of the 286 studies in Vomiting with a site in United States are open now. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States
Ages 18–65 · Healthy volunteers
University of Southern California · Sites in United States
Ages 18–49 · Women only · Healthy volunteers
Vanda Pharmaceuticals · Sites in United States
Ages 18–65 · Healthy volunteers
David Levinthal · Sites in United States
Ages 21–60 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Australia, China and 7 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 57 Vomiting studies recruiting now, 27 (47%) set no upper age limit and 24 (42%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
286 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 68 · Phase 3 54 · Phase 4 34
First in 1999; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is close to the median of 102 across 674 interventional studies indexed under Vomiting.
Median enrollment 86 across the 256 interventional studies, 64 across the 25 observational. Of the 232 that completed or were terminated, 122 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 286 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Simon Williamson Clinic as lead sponsor.
Simon Williamson Clinic has 1 study filed under Vomiting — fewer than ten, so there is no comparison to draw.
15 of the studies in Vomiting with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07446439Phase 3Vanda PharmaceuticalsA Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | 2026-12-01 |
| NCT06382012Phase 3Montefiore Medical CenterAntiemetic Fosaprepitant To Remedy Nausea and Vomiting | 2027-03 |
| NCT05418244Phase 3State University of New York at BuffaloInhaled Isopropyl Alcohol for Treatment of Nausea | 2027-06-30 |
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
Add all 15 to your calendar (.ics) → With an account.
Among the 286 studies in Vomiting with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the proposed study is to provide a clinical approach to chemotherapy induced nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or highly emetogenic chemotherapy for patients who developed breakthrough CINV after cycle 1 based on the available data in the literature as well as the recommendations provided by established guidelines
Chemotherapy-induced nausea and vomiting (CINV) adversely affects patients' quality of life and may affect patients' treatment decisions. The emetogenicity of the chemotherapy administered and specific patient characteristics such as female gender, age, and history of low alcohol intake can increase a patients' risk for CINV.
Table 1. Patient-Related Risk Factors for Emesis Following Chemotherapy Major Factors Minor Factors Female History of Motion Sickness Age \< 50 years Emesis during past pregnancy History of prior low chronic alcohol intake (\<1 ounce of alcohol/day) Anxiety History of previous chemotherapy-induced emesis
Significant and uncontrolled CINV may result in patients returning to the chemotherapy treatment facility one to three days post-chemotherapy for rehydration, or emesis or nausea control. If CINV cannot be controlled in an outpatient facility, patients may subsequently be treated in an emergency department or require hospitalization. Patients who have an electrolyte imbalance or those who have recently undergone surgery or radiation therapy, are at greater risk of experiencing serious complications from CINV.
The use of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists has improved the control of CINV Additional improvement in the control of CINV has occurred with the use of neurokinin-1 (NK-1) receptor antagonists, and olanzapine, an antipsychotic which blocks multiple neurotransmitters in the central nervous system.
The primary endpoint used for studies evaluating various agents for the control of CINV has been complete response (CR) (no emesis, no use of rescue medication) over the acute (24 hours post-chemotherapy), delayed (24-120 hours), and overall (0-120 hours) periods. The combination of a 5-HT3 receptor antagonist, dexamethasone, and a NK-1 receptor antagonist have improved the control of emesis in patients receiving either highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC) over a 120-hour period following chemotherapy administration
The use of effective antiemetic agents in various clinical settings has been described in established guidelines from the Multinational Association of Supportive Care in Cancer (MASCC) and the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO)], and the National Comprehensive Cancer Network (NCCN).
The purpose of the proposed is to provide a clinical approach to CINV prophylaxis in cycle 2 of MEC or HEC for patients who developed breakthrough CINV after cycle 1 based on the available data in the literature as well as the recommendations provided by established guidelines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Add Akynzeo to 5HT3 And dexamethasone
Drug: Akynzeo
olANZAPINE plus Akynzeo
Drug: Akynzeo
OLANZAPINE
Also known as: Olanzapine
COMPELETE RESPONSE, no vomiting or use of rescue medications
No vomiting or use of rescue medications for 5 days post chemotherapy
Time frame: 5 DAYS post chemotherapy
Plan to share: No
Ran from Sep 2023 to primary completion in Nov 2024, 14 months.
Of 41 phase 2 interventional studies under Vomiting, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 14 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Dec 2023 → Nov 2024 and completion Dec 2023 → Nov 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.